Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma

Targeted therapy is currently the standard treatment for advanced hepatocellular carcinoma (HCC), but an effective treatment after the discontinuation of sorafenib therapy remains uncertain. We aim to investigate the survival benefits of transcatheter arterial chemoembolization (TACE) after stopping...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yao-Kuang, Yen, Chieh-Ling, Shiu, Sz-Iuan, Lee, Shou-Wu, Chang, Pi-Yi, Yeh, Hong-Zen, Lee, Teng-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708733/
https://www.ncbi.nlm.nih.gov/pubmed/29190692
http://dx.doi.org/10.1371/journal.pone.0188999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5708733/
https://www.ncbi.nlm.nih.gov/pubmed/29190692
http://dx.doi.org/10.1371/journal.pone.0188999

Ejemplares similares